Vistagen Therapeutics (VTGN) Long-Term Debt Issuances (2010 - 2026)

Vistagen Therapeutics has disclosed Long-Term Debt Issuances across 16 years of filings, most recently posting $96000.0 for Q2 2026.

• In Q2 2026, Long-Term Debt Issuances fell 90.59% year-over-year to $96000.0; the TTM figure through Jun 2026 stood at $96000.0 (down 90.59% YoY), while the FY2026 annual figure was $1.0 million, changed N/A from the prior year.
• Long-Term Debt Issuances came in at $96000.0 for Q2 2026 at Vistagen Therapeutics, down from $1.0 million in the prior quarter.
• In the past five years, Long-Term Debt Issuances ranged from a high of $1.0 million in Q2 2025 to a low of -$1000.0 in Q4 2023.
• Average Long-Term Debt Issuances over 4 years is $348333.3, with a median of $307800.0 recorded in 2022.
• The largest YoY upside for Long-Term Debt Issuances was 155.04% in 2023 against a maximum downside of 100.32% in 2023.
• Over 4 years, Long-Term Debt Issuances stood at $310800.0 in 2022, then tumbled by 100.32% to -$1000.0 in 2023, then soared by 102100.0% to $1.0 million in 2025, then plunged by 90.59% to $96000.0 in 2026.
• Per Business Quant data, the three most recent Long-Term Debt Issuances figures were $96000.0 in Q2 2026, $1.0 million in Q2 2025, and -$1000.0 in Q4 2023.